The Hidden Bottleneck in Pharma Market Access
Before a pharmaceutical company can secure reimbursement and achieve broad patient access in many markets, it must first make a compelling scientific, clinical, economic, and payer-relevant value argument. That argument is often codified through a Health Technology Assessment (HTA) submission, where evidence is assessed by HTA bodies, reimbursement authorities, and payers.
HTA dossiers are not simple documents. They require synthesizing thousands of pages of clinical trial data, regulatory literature, and HEOR (Health Economics and Outcomes Research) evidence. Market access and HEOR teams must align the evidence to the right population, intervention, comparator, outcomes, endpoints, economic assumptions, and country-specific assessment expectations. They must also pressure-test the evidence against likely payer questions around comparator relevance, clinical meaningfulness, uncertainty, cost-effectiveness, and budget impact.
The current reality: Depending on asset complexity, evidence maturity, therapy area, and market requirements, HTA evidence preparation and dossier development can take several months. It absorbs the bandwidth of highly specialized SMEs. And it happens repeatedly. A pharma company may need to prepare, adapt, and localize evidence packages several times a year, sometimes for the same drug across different markets.
The time lost is not just an operational inconvenience. Every week a product sits in evidence collection is a week it is not generating revenue. For drugs with significant market potential, the commercial cost of delay can run into the millions.
This is a workflow where domain expertise is non-negotiable, and where AI, when deployed with the right evidence standards, guardrails, and expert oversight, can significantly reduce manual effort while improving consistency, traceability, and speed.
Why This Is a Managed Services Problem, Not a Technology Problem
The instinct for many organizations is to reach for a point tool: an AI system that can read documents, extract data, and generate summaries. Modern AI can do those things. “But HTA work is not a document-reading problem. It is a judgment problem.”
The evidence that goes into HTA submission will be scrutinized by HTA bodies, payers, and reimbursement authorities who know the therapy area deeply. The data points extracted must be accurate and traceable to the source. The modeling must be defensible. The resulting submission must anticipate and answer the objections that will come.
That level of rigor cannot be delegated to an AI system operating without oversight. It requires domain experts - market access specialists, medical writers, and HEOR analysts - who understand what HTA reviewers, payers, and reimbursement authorities are looking for and can direct the AI accordingly. This is what we mean by Human-in-the-Lead: our domain experts are not reviewers sitting at the end of the process. They are architects of the entire workflow, defining what the AI looks for, evaluating what it surfaces, validating traceability to source, and ensuring that every output meets the evidentiary standard the submission requires.
This is also why AI-enabled HTA support is best positioned as a managed services engagement, not just a project or a pilot. A pharma company's need for HTA submissions does not go away after one submission. It recurs across assets, indications, and markets. The value of a partner who has operationalized the workflow, built the agents, configured the guardrails, and embedded the domain knowledge compounds over time.
What the Workflow Actually Looks Like
Evalueserve's HTA solution addresses three core phases of evidence generation. In practice, the workflow supports the journey from evidence identification to HTA-ready outputs, while keeping expert judgment at the center of every step:
- Systematic Literature Review: Purpose-built AI agents scan and process large volumes of clinical and regulatory documents, often spanning dozens of documents per study, with individual documents potentially running 50 to 100 pages. These agents are configured by our domain experts to know exactly what to look for: specific data types, outcome measures, and evidentiary standards that differ by therapy area and HTA body and market. They extract and structure relevant data points into the formats required for HEOR and HTA modeling. Every extraction is traceable to the source, because HTA reviewers may challenge the evidence basis, endpoint selection, comparator relevance, or assumptions used in the submission.
- Evidence Synthesis and HTA Intelligence: A second layer of agents takes the extracted evidence and feeds it into modeling frameworks that support risk analysis and simulation. Rather than an analyst manually cross-referencing documents to build an evidence base, the agents surface patterns, flag gaps, and generate the structured inputs the market access team needs. Our domain experts then use that intelligence to anticipate regulatory questions, stress-test assumptions, and sharpen the commercial argument.
- Submission Preparation: The synthesized evidence and modeling outputs flow into the submission architecture that our experts have defined. Agents support assembly, drafting, formatting, and cross-referencing work that would otherwise consume weeks of SME time. Our domain experts direct the final packaging, ensuring consistency, compliance, and quality across a document that may run into hundreds of pages.
Throughout every layer, the agents operate within guardrails configured by people who understand what defensible HTA output looks like. The goal is not to replace SME judgment. It is to redirect it: away from low-leverage extraction and formatting tasks, and toward the analytical and strategic work that improves submission readiness and strengthens the value narrative.
What previously took three to four months of intensive SME effort can now be completed in a fraction of the time, without compromising the evidentiary quality that regulators expect. Workflows that previously required three to four months of intensive SME effort can, depending on scope and complexity, be accelerated significantly through AI-enabled extraction, structured synthesis, reusable workflows, and expert validation - while maintaining the evidentiary quality that HTA bodies and payers expect.
The Commercial Case
The value here runs in both directions. On the cost side, reducing the time domain experts spend on literature review and evidence extraction translates directly into reduced cost per submission. On the revenue side, getting to market faster has a commercial value that is difficult to overstate.
For pharmaceutical companies managing multiple products and indications across multiple markets, the ability to run more HTA submissions in parallel, with consistent quality, faster turnaround, reusable evidence assets, and lower cost, represents a fundamental shift in what market access teams can accomplish.
This is not an experiment. It is an operationalized workflow built on 25 years of domain expertise in life sciences and healthcare, with AI embedded at every step and human expertise leading throughout.
The Broader Point for Life Sciences Organizations
HTA is one example of a broader dynamic playing out across pharma and life sciences. There is no shortage of AI solutions promising to transform evidence generation, regulatory affairs, or market access. The gap, as always, is between the demo and production-grade delivery at the standard HTA bodies, payers, regulators, and internal quality teams require.
What closes that gap is not simply a better AI model. It is the domain expertise to configure, direct, and validate the AI's work. It is the managed service infrastructure to sustain that quality across repeated engagements. And it is the commitment to stay as the partner that evolves the workflow as HTA requirements shift, as new evidence types emerge, and as the client's pipeline grows.
That is the engagement model we bring to HTA with PharmaHTAInsight. And it is the model that makes quality AI-led managed services a durable commercial proposition rather than a one-time technology installation.
